MedTrace Logo

Vaccine Therapy in Treating Patients With Advanced Melanoma

NCT00705640 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-12-16

No results posted yet for this study

Summary

RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells.

PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.

Conditions

  • Intraocular Melanoma
  • Malignant Conjunctival Neoplasm
  • Melanoma (Skin)

Interventions

BIOLOGICAL

incomplete Freund's adjuvant

Given subcutaneously and intradermally

BIOLOGICAL

multi-epitope melanoma peptide vaccine

Given subcutaneously and intradermally

BIOLOGICAL

tetanus toxoid helper peptide

Given subcutaneously and intradermally

PROCEDURE

biopsy

Patients undergo surgical biopsy at replicate vaccine site

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Craig L Slingluff, Jr

    lead OTHER

Principal Investigators

  • Craig L. Slingluff, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705640 on ClinicalTrials.gov